Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...

Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage ...

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease ...

Citizens JMP lowered the firm’s price target on Prothena Corporation plc (NASDAQ:PRTA) to $29 from $78 but kept an Outperform ...

Today, we discuss one of these in greater detail. Prothena's program, Prasinezumab, in early Parkinson's disease is the first potentially disease-modifying antibody to demonstrate signals of ...

For Prothena (NASDAQ: PRTA), a huge wave of attention has also come from investors since the start of the year. But has its stock price gone too high too fast? Or is this just a sign of more gains ...

A month has gone by since the last earnings report for Prothena (PRTA). Shares have added about 12.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading ...

Shares of late-stage clinical biotechnology Prothena PRTA surged 88.7% in a year against the industry’s decline of 12.6%. The significant surge is mostly attributable to Prothena’s robust ...